Lyell Immunopharma, INC. filed a current report (8-K)

What happened

Lyell Immunopharma, INC. filed a current report (8-K).

1 independent

SEC EDGARfirst to reportseen 45m ago

Computed by Ansar from the evidence above

Confidence49%

Strongest verification behind this event, aged, and discounted by how sure we are it belongs to this company.

Ecosystem significance28%

How much this moves the ecosystem, independent of your interests.

Promotional language0%

Share of marketing vocabulary detected in the headline and summary.

Concrete detail0

Distinct kinds of checkable fact found: amounts, versions, measured changes.

These are Ansar’s estimates, not source claims. The summary above was assembled from source text, not generated.